InspireMD (NYSE:NSPR) Insider Shane Thomas Gleason Sells 22,778 Shares

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 22,778 shares of the company’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $1.01, for a total transaction of $23,005.78. Following the transaction, the insider owned 1,053,882 shares in the company, valued at $1,064,420.82. This represents a 2.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

InspireMD Trading Up 3.0%

Shares of NYSE NSPR opened at $1.03 on Friday. The firm’s 50-day moving average price is $1.39 and its 200-day moving average price is $1.67. InspireMD, Inc. has a 1-year low of $0.97 and a 1-year high of $2.93. The firm has a market capitalization of $48.24 million, a P/E ratio of -1.37 and a beta of 0.82.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC bought a new position in shares of InspireMD during the 1st quarter valued at approximately $29,000. XTX Topco Ltd bought a new position in shares of InspireMD during the 4th quarter valued at approximately $30,000. Virtu Financial LLC bought a new position in shares of InspireMD during the 4th quarter valued at approximately $31,000. Creative Planning bought a new position in shares of InspireMD during the 2nd quarter valued at approximately $44,000. Finally, Legato Capital Management LLC bought a new position in shares of InspireMD during the 4th quarter valued at approximately $48,000. 44.78% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NSPR has been the subject of a number of recent analyst reports. Maxim Group initiated coverage on shares of InspireMD in a research report on Monday, February 2nd. They issued a “buy” rating and a $6.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 price objective (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Loop Capital set a $5.00 price objective on shares of InspireMD in a research report on Tuesday, February 24th. Finally, Lake Street Capital set a $4.00 price objective on shares of InspireMD in a research report on Monday, May 4th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $4.50.

Key Headlines Impacting InspireMD

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: There were no clearly positive company-specific announcements in the latest items, so investor attention is centered on the stock’s low valuation and recent trading near its 1-year low. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The most recent insider sale was small and attributed to tax withholding obligations tied to equity award vesting, which often makes the transactions less concerning than open-market selling. Multiple similar sales were also reported earlier this year. SEC filing
• Negative Sentiment: Repeated insider sales can still weigh on sentiment, as investors may view them as a sign of limited near-term upside or a lack of conviction from management, especially for a small-cap stock already trading below its recent moving averages. SEC filing

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.